Journey Medical (DERM) Gross Margin (2020 - 2026)

Journey Medical's Gross Margin history runs 7 years deep, the most recent figure standing at 60.94% for Q1 2026.

• Quarterly Gross Margin fell 260.0% year-over-year to 60.94% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 65.09% (up 70.0% YoY) and the FY2025 annual result came in at 66.17%, up 404.0% from the prior year.
• Gross Margin was 60.94% for Q1 2026 at Journey Medical, down from 66.17% in the prior quarter.
• Across five years, Gross Margin topped out at 85.27% in Q4 2023 and bottomed at 46.99% in Q1 2023.
• A 5-year average of 62.65% and a median of 61.45% in 2024 frame the typical range for Gross Margin.
• Annual changes were most pronounced in 2023 — Gross Margin surged 3374 bps — and 2024, when it tumbled 2235 bps.
• Journey Medical's Gross Margin stood at 51.52% in 2022, then surged by 65 bps to 85.27% in 2023, then dropped by 26 bps to 62.92% in 2024, then climbed by 5 bps to 66.17% in 2025, then slipped by 8 bps to 60.94% in 2026.
• Business Quant data shows DERM's Gross Margin at 60.94% in Q1 2026, 66.17% in Q4 2025, and 66.2% in Q3 2025.